Kimryn Rathmell, Chief Executive Officer of Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute, shared a post on LinkedIn:
“When we share the inspirational stories of modern cancer immunology and immunotherapy, it is clear there is far too much here we are taking for granted. Groundbreaking research over past decades has opened up innumerable new avenues to understand and harness the immune system to treat cancer.
This work has been undertaken by hundreds (thousands) of dedicated researchers, in labs and clinics, across the country, pushing back the boundaries of science. It has been a major investment of federal funding, institutions, and foundations. One such foundation is Cancer Research Institute (CRI), who focuses funding to support building this talent pipeline by supporting early career investigators.
This year’s annual gala highlighted some of this work, and included powerful sharing of patient stories – from the earliest days, when disease control represented a miracle, to more recent patients, where cure occurs at a reliable and expected rate. All thanks to immunotherapy.
Cancer Research Institute (CRI) also recognized major contributors to the field with Coley Medal (Aviv Regev and Alan Korman), recognition honoring the incredible work of Jed Wolchok, and the Fred Alt Award, given to none other than Jeffrey Rathmell, who was introduced by Kunle Odunsi and who shared remarks on his journey in immunometabolism.
It was a lovely event which expertly demonstrated the impact of support for cancer research, the value in supporting early career investigators, the commitment of scientists working in this field, and the urgency of work remaining to make immunotherapy achieve its fullest promise for all patients.
Incredibly nice as well that Fred Alt was there to recognize Jeffrey Rathmell!”
Read more posts featuring Kimryn Rathmell on OncoDaily.